This time last year, Seattle biotech company Juno Therapeutics was on its way to having the first CAR T immunotherapy treatment on the market. But a clinical trial of its… Read More
ReplyYes, a fast-growing, chat-based commerce startup, announced three additions to the company’s executive board this week: former Zulily engineer Trevor Inman, former Qumulo exec Brett Goodwin, and Blackberry and Warner Music… Read More
Juno Therapeutics announced Monday that a former Genentech executive, Dr. Sunil Agarwal, has joined the company as its new President of Research and Development — part of a new office for… Read More
Seattle-based cancer immunotherapy company Juno Therapeutics handily beat analyst expectations for the fourth quarter, posting $21.2 million in revenue, compared to an expected $14.6 million, with a loss of 51 cents a… Read More
New data from Seattle’s Juno Therapeutics shows promising results for one of its immunotherapy treatments, JCAR017. The drug was studied as a treatment for severely sick patients with non-Hodgkin lymphoma, and the most… Read More
Juno Therapeutics announced last week that it was placing a voluntary hold on its clinical trial of JCAR015 — an experimental but promising immunotherapy treatment for patients with advanced leukemia —… Read More
Juno Therapeutics, the Seattle-based biotech company developing immunotherapy treatments for cancer, announced it has placed a voluntary hold on the clinical trial of its JCAR015 cancer treatment, following two patient deaths… Read More
What does it take for a region to become truly revolutionary? Dr. Richard Klausner, co-founder and director of biotechnology company Juno Therapeutics, says it is all about time, place, and capitalizing on unique… Read More
While Washington state’s biotech industry is on the up and up, it still lags far behind hubs like San Francisco and Cambridge, Mass. Washington’s biotech industry is not only lagging… Read More
Juno Therapeutics, the Seattle-based clinical cancer research firm is doing groundbreaking work in seeking a cure for the disease. CEO Hans Bishop said at the GeekWire Summit on Tuesday that… Read More
Seattle boasts the fifth strongest life sciences market in the country, according to a new report from Jones Lang LaSalle, led by world-renowned institutions and startups that have grown to… Read More
A study published today on a Juno Therapeutics immunotherapy treatment for blood cancers shows that the drug and others like it could be more effective and less toxic than other treatments. The… Read More
Juno Therapeutics, a Seattle-based clinical cancer research firm valued at $3.8 billion, has been sued in a class-action lawsuit alleging that the company violated federal securities law. Juno and its CEO Hans… Read More
It’s been a busy quarter for Juno Therapeutics with several different immunotherapy trials underway and a big hiring push as it expands research capabilities. The Seattle-based biotech giant, which re-engineers the… Read More
Seattle-based Juno Therapeutics has acquired RedoxTherapies for $10 million, to secure exclusive rights to a molecule that may provide a new cancer treatment. The molecule, called vipadenant, may help the immune… Read More
Seattle-based Juno Therapeutics says it’s resuming a clinical trial of its immunotherapy treatment, a week after the Food and Drug Administration ordered a hold due to the deaths of three… Read More
The U.S. Food and Drug Administration placed a hold on a Juno Therapeutics clinical trial of a treatment for a form of leukemia following the death of two trial patients… Read More
Editas Medicine filed the paperwork for an initial public offering today, marking a first for the growing number of private ventures that aim to take advantage of a powerful gene-editing… Read More
It has been another giant year for technology and science in the Seattle region — featuring everything from rocket launches to big financing rounds to breakthrough devices and huge acquisitions.… Read More
Nohla Therapeutics just became the latest biotech startup to come out of the Fred Hutchinson Cancer Research Center. Like spinouts before it, Nohla is already well on its way to becoming one of Seattle’s rising… Read More
Juno Therapeutics missed analyst expectations with its Q3 earnings report on Tuesday, posting a net loss of $47.6 million, or 53 cents per share, on $1.6 million in revenue. Analysts… Read More
—Lighter Capital appointed Rebecca Conner as a director of its investment team. The Techstars mentor will work with companies in the Pacific Northwest, the Rocky Mountain region and Texas in the Seattle-based Lighter… Read More
Juno Therapeutics, a Seattle-based cancer research firm backed by Amazon founder Jeff Bezos, Arch Venture Partners and others, reported a loss of $66 million on $12 million in revenue during the… Read More
Shares of Seattle-based biotech startup Juno Therapeutics spiked more than 60 percent in after-hours trading on Monday after the company announced a $1 billion investment from Celgene. The 10-year “collaboration” will… Read More
Juno Therapeutics has paid $59 million to acquire Stage Cell Therapeutics, a privately held biotech company based in Germany. Stage Cell, which is privately held, is known for its cell… Read More
Seattle-based cancer research startup Juno Therapeutics today reached a settlement with Novartis Pharmaceuticals Corp. over a three-year patent dispute. The original lawsuit was brought forward in 2012, when St. Jude Children’s… Read More
Seattle-based cancer research startup Juno Therapeutics today fell short of analyst estimates in its first earnings report. Juno posted a non-GAAP net loss of $22.7 million, or $1.61 per share. Wall Street… Read More
Juno Therapeutics is just a little more than a year old, but the Seattle area biotech startup has quite the following on Wall Street. The company’s stock closed today at… Read More
Juno Therapeutics‘ first day as a public company is in the books — and it certainly was a good one. The Seattle biotech startup priced its initial public offering Thursday… Read More
Fast-moving Juno Therapeutics is moving closer to becoming a publicly-traded company. The Seattle biotechnology company today updated is IPO filing with the SEC, indicating that it plans to price shares… Read More